Illumina's Divestment of Grail Marks the End of a Troubled Merger Attempt

Illumina, the leading maker of DNA sequencing machines, has announced that it will divest Grail, the developer of a multi-cancer screening test, following a court decision that deemed their merger anti-competitive. Illumina plans to sell or list Grail on capital markets by the end of the second quarter of 2024, marking the end of a disastrous attempted merger that began in 2016 when Illumina spun out Grail to raise funds before re-acquiring it for $7.1 billion in 2020.